Results 1 to 10 of about 85,257 (242)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

SAGE Open Medical Case Reports, 2023
Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura, Daisuke Ichikura, Miwa Hinata, Noriko Hida, Toshiyuki Baba   +4 more
doaj   +1 more source

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Liver Cancer, 2023
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda   +13 more
doaj   +1 more source

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer Medicine, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐small cell lung cancer (
Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang   +17 more
doaj   +1 more source

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Pharmaceuticals, 2020
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA.
Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi   +7 more
doaj   +1 more source

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits [PDF]

International Journal of Ophthalmology, 2015
AIM:To investigate the pharmacokinetics and distributions of bevacizumab by intravitreal injection of prepared bevacizumab-poly (L-lactic-co-glycolic acid) (PLGA) microspheres in rabbits, to provide evidence for clinical application of this kind of ...
Zhuo Ye, Yan-Li Ji, Xiang Ma, Jian-Guo Wen, Wei Wei, Shu-Man Huang   +5 more
doaj   +1 more source

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Case Reports in Neurology, 2016
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields ...
George Ansstas, David D. Tran
doaj   +1 more source

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Drugs in R&D, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional
Di Cao, Chunping Deng, Guangying Wang, Xiong Mei, Jianhua Xie, Yuanmei Liu, Yujie Liu, Yili Yang, Shengfeng Li, Cuihua Liu   +9 more
doaj   +1 more source

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers

Разработка и регистрация лекарственных средств, 2019
Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors.
M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov   +12 more
doaj   +1 more source

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization

Veterinary Sciences, 2023
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to ...
Ulrike Lessiak, Barbara Pratscher, Alexander Tichy, Barbara Nell   +3 more
doaj   +1 more source